These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29602400)

  • 1. Targeting Glucosylceramide Synthesis in the Treatment of Rare and Common Renal Disease.
    Shayman JA
    Semin Nephrol; 2018 Mar; 38(2):183-192. PubMed ID: 29602400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosphingolipids and kidney disease.
    Mather AR; Siskind LJ
    Adv Exp Med Biol; 2011; 721():121-38. PubMed ID: 21910086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models.
    Natoli TA; Smith LA; Rogers KA; Wang B; Komarnitsky S; Budman Y; Belenky A; Bukanov NO; Dackowski WR; Husson H; Russo RJ; Shayman JA; Ledbetter SR; Leonard JP; Ibraghimov-Beskrovnaya O
    Nat Med; 2010 Jul; 16(7):788-92. PubMed ID: 20562878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of glucosylceramide synthase.
    Shayman JA; Lee L; Abe A; Shu L
    Methods Enzymol; 2000; 311():373-87. PubMed ID: 10563341
    [No Abstract]   [Full Text] [Related]  

  • 5. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.
    Abe A; Arend LJ; Lee L; Lingwood C; Brady RO; Shayman JA
    Kidney Int; 2000 Feb; 57(2):446-54. PubMed ID: 10652021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Glycosphingolipid Metabolism to Treat Kidney Disease.
    Shayman JA
    Nephron; 2016; 134(1):37-42. PubMed ID: 26954668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucosylceramide synthase: assay and properties.
    Shayman JA; Abe A
    Methods Enzymol; 2000; 311():42-9. PubMed ID: 10563309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of Glucosylceramide Synthase.
    Shayman JA; Hinkovska-Galcheva V; Shu L
    Methods Mol Biol; 2023; 2613():271-288. PubMed ID: 36587085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translational Aspects of Sphingolipid Metabolism in Renal Disorders.
    Abou Daher A; El Jalkh T; Eid AA; Fornoni A; Marples B; Zeidan YH
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse.
    Deshmukh GD; Radin NS; Gattone VH; Shayman JA
    J Lipid Res; 1994 Sep; 35(9):1611-8. PubMed ID: 7806975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer.
    Kartal Yandım M; Apohan E; Baran Y
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):13-20. PubMed ID: 23073611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of glucosylceramide synthesis by Golgi-localized phosphoinositide.
    Ishibashi Y; Ito M; Hirabayashi Y
    Biochem Biophys Res Commun; 2018 May; 499(4):1011-1018. PubMed ID: 29627573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in composition of newly synthesized sphingolipids of HeLa cells during the cell cycle -- suppression of sphingomyelin and higher-glycosphingolipid synthesis and accumulation of ceramide and glucosylceramide in mitotic cells.
    Yokoyama K; Suzuki M; Kawashima I; Karasawa K; Nojima S; Enomoto T; Tai T; Suzuki A; Setaka M
    Eur J Biochem; 1997 Oct; 249(2):450-5. PubMed ID: 9370353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy.
    Fox TE; Han X; Kelly S; Merrill AH; Martin RE; Anderson RE; Gardner TW; Kester M
    Diabetes; 2006 Dec; 55(12):3573-80. PubMed ID: 17130506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus.
    Zador IZ; Deshmukh GD; Kunkel R; Johnson K; Radin NS; Shayman JA
    J Clin Invest; 1993 Mar; 91(3):797-803. PubMed ID: 8450061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects of short-chain ceramide and glucosylceramide on sphingolipids and protein kinase C.
    Abe A; Wu D; Shayman JA; Radin NS
    Eur J Biochem; 1992 Dec; 210(3):765-73. PubMed ID: 1483461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosphingolipid metabolism and polycystic kidney disease.
    Natoli TA; Modur V; Ibraghimov-Beskrovnaya O
    Cell Signal; 2020 May; 69():109526. PubMed ID: 31911181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice.
    Shen JS; Meng XL; Wight-Carter M; Day TS; Goetsch SC; Forni S; Schneider JW; Liu ZP; Schiffmann R
    Hum Mol Genet; 2015 Jun; 24(11):3181-91. PubMed ID: 25701874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity?
    Shayman JA
    Trans Am Clin Climatol Assoc; 2013; 124():46-60. PubMed ID: 23874009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.